Utama › Kolitis Ulseratif › Utah
Kajian klinikal Kolitis Ulseratif di Utah
7 kajian untuk Kolitis Ulseratif sedang mencari peserta di lokasi di Utah.
Bandar di Utah
Teks kajian rasmi (Bahasa Inggeris)
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Care Access-Ogden, Ogden
- Advanced Research Institute - South Ogden, Ogden
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06598943A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- University of Utah Hospitals & Clinics, Salt Lake City
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06979336A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- University of Utah, Salt Lake City
Mengambil pesertaFasa 3
Umur 3 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06663332LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Care Access - Ogden, Ogden
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07186101A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- University of Utah Health, Salt Lake City
Mengambil pesertaFasa 4
Umur 18 hingga 65 · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06095128An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Velocity Clinical Research, Salt Lake City - Site Number: 8400147, West Jordan
Mengambil pesertaFasa 3
Umur 16 hingga 80 · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07184996Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Utah Health, Salt Lake City
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT05230173Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.